Dual-Pathway Inhibition: A New Frontier in Leiomyosarcoma Management
The combination of cabozantinib and temozolomide achieved a 12-week progression-free survival (PFS) rate of 74% in patients with advanced leiomyosarcoma.
Dual targeting of the VEGF and MET pathways alongside alkylating chemotherapy represents a novel mechanistic approach for soft tissue sarcomas.
The treatment regimen demonstrated a manageable safety profile, with hematologic toxicities being the most frequent high-grade adverse events.
